Full Press Release Details
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Summit Therapeutics Inc. (NASDAQ: SMMT). The investigation focuses on Summit’s executive officers and whether investor losses may be recovered under federal securities laws.
What if I purchased Summit securities?
If you purchased Summit securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.
Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.
There is no cost or obligation to you.
Background of the investigation
On April 30, 2026, Summit reported its first quarter 2026 financial results and provided an update concerning the HARMONi-3 Phase III clinical trial. Among other things, the Company disclosed that, although it had previously announced its intention to perform an interim progression-free survival analysis for the squamous cohort of the HARMONi-3 study, “[t]o achieve statistical significance, there was a meaningfully higher bar than the upcoming planned final PFS analysis based on the minimal alpha spent on the interim analysis.” Summit further disclosed that, following review of the early interim PFS analysis by the Independent Data Monitoring Committee, the committee recommended that the study continue as planned.
Following this disclosure, Summit’s stock price declined sharply, damaging investors.
In light of this disclosure, Johnson Fistel is investigating whether Summit complied with the federal securities laws. If you suffered losses from your investment in Summit stock, contact Johnson Fistel.
About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm’s effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | jimb@johnsonfistel.com | fjohnson@johnsonfistel.com